Morningstar

Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy

HOUSTON, Feb. 16, 2026 /PRNewswire/ -- New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) ...
Morningstar

New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy

Data from the GEICAM/9906 trial, presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024, provides independent confirmation of the predictive value of the Endocrine Activity ...